Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-09-05-Speech-2-322"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-09-05"^^xsd:date2
dcterms:Is Part Of	lp_eu:Counterfeiting of medicines (debate)2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20060905.26.2-322"2
lpv:hasSubsequent	lp_eu:2006-09-05-Speech-2-3232
lpv:speaker	lp:Maria Martens2
lpv:spokenAs	member_of_the_bureau; EPP-ED (2004-08-31--2009-07-13)3 unknown; Christen Democratisch Appèl (2004-07-20--2009-07-13)3 substitute; FEMM (2004-09-08--2007-01-14)3 member; DEVE (2004-07-21--2007-01-14)3 substitute; Delegation for relations with the countries of Central America (2004-09-16--2007-03-13)3 substitute; INTA (2004-07-22--2007-01-14)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2004-09-15--2009-07-13)3
lpv:translated text	". Mr President, I too should like to express my concern about the problems surrounding counterfeit medicines. Counterfeit medicines are manufactured and traded illegally without any form of supervision. Their effects cannot be checked, which makes them a potential risk to public health, and so this piracy should be stopped. Mr Cornillet already broached the subject, the Commissioner mentioned it as well and I welcome every measure the Commission takes to tackle this problem. Since problems mainly occur in the developing countries, the poor countries, that is also where I can foresee the biggest problems when it comes to dealing with this piracy efficiently and adequately. In those countries, the supply of reliable, legal medicines is often not organised as well as it is in Europe. That is why traders in counterfeit medicines have relatively more scope to sell their medicines, the effect of which cannot be checked and can, consequently, even be harmful to public health. In addition, developing countries often lack an adequate legal framework. Their laws are simply not adequate to the task of addressing this problem effectively. Even when these are in place, monitoring leaves a great deal to be desired. In developing countries, there is a need for affordable, effective and, of course, legal medicines, and that is why I should like to mention the scope which generic medicines offer. They cannot make the problem go away, but can go some way towards alleviating the need that exists. Unfortunately, little use is being made of them at the moment. More could be done perhaps in that area. The Commissioner claimed that an international convention or standard is not enough, but I can well imagine that one could make a difference, and if it proves inadequate, then more should be done. I take the view that a clear and universal approach is extremely important. Europe will need to do its bit, and that also involves the transfer of knowledge, in order to address the fight against counterfeit medicines more effectively. I would like to know – and the Commissioner has already partly answered in his explanation – what the new plans are for tackling counterfeit medicines and the organisation in this respect, particularly where criminal activity is concerned, in future."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph